Publications

Abdulghani J, Gu L, Dagvadorj A, Lutz J, et al. (2008). Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172: 1717-1728. http://dx.doi.org/10.2353/ajpath.2008.071054 PMid:18483213    PMCid:2408430 Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. http://dx.doi.org/10.1093/bioinformatics/bth457 PMid:15297300 Barrett JC, Hansoul S, Nicolae DL, Cho JH, et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40: 955-962. http://dx.doi.org/10.1038/ng.175 PMid:18587394    PMCid:2574810 Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102. http://dx.doi.org/10.1016/j.ccr.2009.01.002 PMid:19185844 Bowman T, Garcia R, Turkson J and Jove R (2000). STATs in oncogenesis. Oncogene 19: 2474-2488. http://dx.doi.org/10.1038/sj.onc.1203527 PMid:10851046 Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, et al. (1999). Stat3 as an oncogene. Cell 98: 295-303. http://dx.doi.org/10.1016/S0092-8674(00)81959-5 Darnell JE (2005). Validating Stat3 in cancer therapy. Nat. Med. 11: 595-596. http://dx.doi.org/10.1038/nm0605-595 PMid:15937466 Dauer DJ, Ferraro B, Song L, Yu B, et al. (2005). Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408. http://dx.doi.org/10.1038/sj.onc.1208469 PMid:15735721 Ferguson LR, Han DY, Fraser AG, Huebner C, et al. (2010). Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat. Res. 690: 108-115. http://dx.doi.org/10.1016/j.mrfmmm.2010.01.017 PMid:20109474 Fletcher S, Drewry JA, Shahani VM, Page BD, et al. (2009). Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 87: 825-833. http://dx.doi.org/10.1139/O09-044 PMid:19935868 Grivennikov SI and Karin M (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21: 11-19. http://dx.doi.org/10.1016/j.cytogfr.2009.11.005 Horinaga M, Okita H, Nakashima J, Kanao K, et al. (2005). Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66: 671-675. http://dx.doi.org/10.1016/j.urology.2005.03.066 PMid:16140113 Hsieh FC, Cheng G and Lin J (2005). Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun. 335: 292-299. http://dx.doi.org/10.1016/j.bbrc.2005.07.075 PMid:16081048 Hsu HS, Huang PI, Chang YL, Tzao C, et al. (2011). Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117: 2970-2985. http://dx.doi.org/10.1002/cncr.25869 PMid:21225866 Ito N, Eto M, Nakamura E, Takahashi A, et al. (2007). STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25: 2785-2791. http://dx.doi.org/10.1200/JCO.2006.09.8897 PMid:17602083 Jing N, Zhu Q, Yuan P, Li Y, et al. (2006). Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther. 5: 279-286. http://dx.doi.org/10.1158/1535-7163.MCT-05-0302 PMid:16505101 Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436. http://dx.doi.org/10.1038/nature04870 PMid:16724054 Kreil S, Waghorn K, Ernst T, Chase A, et al. (2010). A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 95: 148-152. http://dx.doi.org/10.3324/haematol.2009.011510 PMid:20065083    PMCid:2805737 Lai SY and Johnson FM (2010). Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist. Updat. 13: 67-78. http://dx.doi.org/10.1016/j.drup.2010.04.001 PMid:20471303 Lin Q, Lai R, Chirieac LR, Li C, et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167: 969-980. http://dx.doi.org/10.1016/S0002-9440(10)61187-X Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108. http://dx.doi.org/10.3322/canjclin.55.2.74 Sansone P, Storci G, Tavolari S, Guarnieri T, et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117: 3988-4002. http://dx.doi.org/10.1172/JCI32533 PMid:18060036    PMCid:2096439 Scagliotti GV, Longo M and Novello S (2009). Nonsmall cell lung cancer in never smokers. Curr. Opin. Oncol. 21: 99-104. http://dx.doi.org/10.1097/CCO.0b013e328321049e PMid:19532009 Shields PG (2002). Molecular epidemiology of smoking and lung cancer. Oncogene 21: 6870-6876. http://dx.doi.org/10.1038/sj.onc.1205832 PMid:12362269 Siddiquee K, Zhang S, Guida WC, Blaskovich MA, et al. (2007a). Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 104: 7391-7396. http://dx.doi.org/10.1073/pnas.0609757104 PMid:17463090    PMCid:1863497 Siddiquee KA, Gunning PT, Glenn M, Katt WP, et al. (2007b). An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2: 787-798. http://dx.doi.org/10.1021/cb7001973 PMid:18154266 Stephens M, Smith NJ and Donnelly P (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989. http://dx.doi.org/10.1086/319501 PMid:11254454 Turkson J (2004). STAT proteins as novel targets for cancer drug discovery. Expert. Opin. Ther. Targets. 8: 409-422. http://dx.doi.org/10.1517/14728222.8.5.409 PMid:15469392 Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, et al. (2007). Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr. Relat. Cancer 14: 267-277. http://dx.doi.org/10.1677/ERC-06-0077 PMid:17639043 Weerasinghe P, Garcia GE, Zhu Q, Yuan P, et al. (2007). Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol. 31: 129-136. PMid:17549413 Yang L, Parkin DM, Li LD, Chen YD, et al. (2004). Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br. J. Cancer 90: 2157-2166. PMid:15150609    PMCid:2409509 Yin W, Cheepala S, Roberts JN, Syson-Chan K, et al. (2006). Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol. Cancer 5: 15. http://dx.doi.org/10.1186/1476-4598-5-15 PMid:16603078    PMCid:1502137 Yin ZJ, Jin FG, Liu TG, Fu EQ, et al. (2010). Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J. Surg. Res. Doi: 10.1016/j.jss.2010.03.053. http://dx.doi.org/10.1016/j.jss.2010.03.053 PMid:20605584 Yu H and Jove R (2004). The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4: 97-105. http://dx.doi.org/10.1038/nrc1275 PMid:14964307 Yu H, Pardoll D and Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809. http://dx.doi.org/10.1038/nrc2734 PMid:19851315